Skip to main content

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated · Phase 3 · NCT03744910

Conditions: Antibody-mediated Rejection

At a glance

Research payments reported, 2025
$566,710
U.S. investigators named
28
Sites paid
29
Planned or actual enrollment
194

About the trial

Sponsor
CSL Behring (with ICON Clinical Research)
Tested
Clazakizumab (biological), Physiologic saline solution (drug)
Dates
Started 2019-10-14; completion 2024-04-08
Results posted
Yes

This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.

From ClinicalTrials.gov, last updated 2025-07-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Csl Behring reported $566,710 in research payments for this study in 2025 (105 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.